<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620616</url>
  </required_header>
  <id_info>
    <org_study_id>RELX-002</org_study_id>
    <nct_id>NCT04620616</nct_id>
  </id_info>
  <brief_title>Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by ENDS Consumers</brief_title>
  <official_title>A Randomized, Open-Label, Multi-Center, Cross-Over Study of Adult Electronic Nicotine Delivery Systems (ENDS) Consumers to Assess Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With RELX Infinity ENDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cheerain HK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cheerain HK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate nicotine uptake, the potential abuse liability, and&#xD;
      puffing topography associated with the use of an electronic nicotine delivery system (ENDS)&#xD;
      with tobacco- and menthol-flavored e-liquids in current ENDS consumers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2020</start_date>
  <completion_date type="Actual">January 14, 2021</completion_date>
  <primary_completion_date type="Actual">January 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nicotine uptake</measure>
    <time_frame>120 minutes</time_frame>
    <description>PK Session baseline-adjusted maximum plasma nicotine concentration [Cmax]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nicotine uptake</measure>
    <time_frame>120 minutes</time_frame>
    <description>PK Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-120)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nicotine uptake - PK Session</measure>
    <time_frame>15 minutes</time_frame>
    <description>PK Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-15)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine uptake - PK Session</measure>
    <time_frame>120 minutes</time_frame>
    <description>PK Session time of the maximum post-baseline nicotine concentration [Tmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine uptake - Ad Libitum Session</measure>
    <time_frame>480 minutes</time_frame>
    <description>Ad Libitum Session baseline-adjusted area under the nicotine concentration-time curve [AUC(0-480)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject effects as measured by the Modified Product Evaluation Scale</measure>
    <time_frame>480 minutes</time_frame>
    <description>Subjective product assessments during the Ad Libitum Session as measured by responses to the Modified Product Evaluation Scale (scale range of 1 [not at all] to 7 [extremely])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject effects as measured by the Future Intent to Use questionnaire</measure>
    <time_frame>480 minutes</time_frame>
    <description>Subjective product assessments during the Ad Libitum Session as measured by responses to the Future Intent to Use questionnaire (visual analog scale range of &quot;Definitely Would Not&quot; to &quot;Definitely Would&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject effects as measured by the Urge to Vape questionnaire</measure>
    <time_frame>120 minutes</time_frame>
    <description>Subjective product assessments during the PK Session as measured by responses to the Urge to Vape questionnaire (visual analog scale range of &quot;Not at All&quot; to &quot;Extreme&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject effects as measured by the Product Liking questionnaire</measure>
    <time_frame>120 minutes</time_frame>
    <description>Subjective product assessments during the PK Session as measured by responses to the Product Liking questionnaire (visual analog scale range of &quot;Not at All&quot; to &quot;Extremely&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic effects as measured by heart rate</measure>
    <time_frame>480 minutes</time_frame>
    <description>Heart rate measurements during the Ad Libitum Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic effects as measured by heart rate</measure>
    <time_frame>120 minutes</time_frame>
    <description>Heart rate measurements during the PK Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic effects as measured by blood pressure</measure>
    <time_frame>480 minutes</time_frame>
    <description>Blood pressure measurements during the Ad Libitum Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic effects as measured by blood pressure</measure>
    <time_frame>120 minutes</time_frame>
    <description>Blood pressure measurements during the PK Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>480 minutes</time_frame>
    <description>Change in weight of study products during the Ad Libitum Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>480 minutes</time_frame>
    <description>Number of requests to use the study products during the Ad Libitum Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>60 minutes</time_frame>
    <description>Number of puffs taken from the study products during the Ad Libitum Session topography assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>60 minutes</time_frame>
    <description>Duration of puffs taken from the study products during the Ad Libitum Session topography assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>60 minutes</time_frame>
    <description>Volume of puffs taken from the study products during the Ad Libitum Session topography assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>60 minutes</time_frame>
    <description>Flow rate of puffs taken from the study products during the Ad Libitum Session topography assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>60 minutes</time_frame>
    <description>Inter-puff interval of puffs taken from the study products during the Ad Libitum Session topography assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>5 minutes</time_frame>
    <description>Change in weight of study products during the PK Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study product use</measure>
    <time_frame>5 minutes</time_frame>
    <description>Number of puffs taken from the study products during the PK Session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of product-use emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of product malfunction or misuse</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Electronic Cigarette Use</condition>
  <arm_group>
    <arm_group_label>Product Use Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Products use sequence:&#xD;
Period 1 - RELX ENDS tobacco flavor Period 2 - RELX ENDS menthol flavor Period 3 - Usual Brand ENDS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Use Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Products use sequence:&#xD;
Period 1 - RELX ENDS menthol flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS tobacco flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Use Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Products use sequence:&#xD;
Period 1 - Usual Brand ENDS Period 2 - RELX ENDS tobacco flavor Period 3 - RELX ENDS menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Use Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Products use sequence:&#xD;
Period 1 - Usual Brand ENDS Period 2 - RELX ENDS menthol flavor Period 3 - RELX ENDS tobacco flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Use Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Products use sequence:&#xD;
Period 1 - RELX ENDS tobacco flavor Period 2 - Usual Brand ENDS Period 3 - RELX ENDS menthol flavor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product Use Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Products use sequence:&#xD;
Period 1 - RELX ENDS menthol flavor Period 2 - RELX ENDS tobacco flavor Period 3 - Usual Brand ENDS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RELX ENDS Tobacco Flavor</intervention_name>
    <description>Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions</description>
    <arm_group_label>Product Use Sequence 1</arm_group_label>
    <arm_group_label>Product Use Sequence 2</arm_group_label>
    <arm_group_label>Product Use Sequence 3</arm_group_label>
    <arm_group_label>Product Use Sequence 4</arm_group_label>
    <arm_group_label>Product Use Sequence 5</arm_group_label>
    <arm_group_label>Product Use Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RELX ENDS Menthol Flavor</intervention_name>
    <description>Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions</description>
    <arm_group_label>Product Use Sequence 1</arm_group_label>
    <arm_group_label>Product Use Sequence 2</arm_group_label>
    <arm_group_label>Product Use Sequence 3</arm_group_label>
    <arm_group_label>Product Use Sequence 4</arm_group_label>
    <arm_group_label>Product Use Sequence 5</arm_group_label>
    <arm_group_label>Product Use Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Subject Usual Brand ENDS</intervention_name>
    <description>Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions</description>
    <arm_group_label>Product Use Sequence 1</arm_group_label>
    <arm_group_label>Product Use Sequence 2</arm_group_label>
    <arm_group_label>Product Use Sequence 3</arm_group_label>
    <arm_group_label>Product Use Sequence 4</arm_group_label>
    <arm_group_label>Product Use Sequence 5</arm_group_label>
    <arm_group_label>Product Use Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provides voluntary consent to participate in the study as documented on the signed&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          2. Is 22 to 59 years of age, inclusive, at the time of consent.&#xD;
&#xD;
          3. Has been a daily ENDS consumer for at least 3 months prior to Screening and through&#xD;
             Check-in. Brief periods of abstinence (e.g., up to ~7 consecutive days due to illness,&#xD;
             trying to quit, participation in a study where vaping was prohibited) ≥ 30 days prior&#xD;
             to Screening will be permitted at the discretion of an Investigator.&#xD;
&#xD;
          4. Reports weekly use of at least 3 mL of e-liquid from an ENDS product at Screening.&#xD;
&#xD;
          5. Has a urine cotinine concentration ≥ of 200 ng/mL at Screening and Check-in.&#xD;
&#xD;
          6. Has an exhaled carbon monoxide (ECO) concentration &lt; 10 ppm at Check-in.&#xD;
&#xD;
          7. If female, must meet one of the following criteria:&#xD;
&#xD;
             If of childbearing potential - agrees to use one of the accepted contraceptive&#xD;
             regimens from at least 30 days prior to the first product use, during the study, and&#xD;
             for at least 30 days after the last product use. An acceptable method of contraception&#xD;
             includes one of the following: abstinence from heterosexual intercourse, hormonal&#xD;
             contraceptives (birth control pills, injectable/implant/insertable hormonal birth&#xD;
             control products, transdermal patch), intrauterine device (with or without hormones)&#xD;
             OR agrees to use a double barrier method (e.g. condom and spermicide) during the study&#xD;
             and for at least 30 days after the last product use.&#xD;
&#xD;
             If a female of non-childbearing potential - should be surgically sterile (i.e. has&#xD;
             undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion)&#xD;
             or in a menopausal state (at least 1 year without menses), as confirmed by FSH levels&#xD;
             (≥ 40 mIU/mL).&#xD;
&#xD;
          8. Is willing to comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history or presence of clinically significant uncontrolled gastrointestinal,&#xD;
             renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary,&#xD;
             immunologic, psychiatric, or cardiovascular disease, or any other condition that would&#xD;
             jeopardize the safety of the subject or impact the validity of the study results.&#xD;
&#xD;
          2. Has a clinically significant abnormal finding on the physical examination, medical&#xD;
             history, vital signs, ECG, or clinical laboratory results.&#xD;
&#xD;
          3. Has a positive test for HIV-1/HIV-2 Antibodies, Hepatitis B surface Antigen, or&#xD;
             Hepatitis C Antibody.&#xD;
&#xD;
          4. Has had an acute illness (e.g., upper respiratory infection, viral infection) within&#xD;
             14 days prior to Check-in.&#xD;
&#xD;
          5. Has a fever (&gt; 100.5°F) at Screening or Check-in.&#xD;
&#xD;
          6. Has a positive COVID-19 test during the screening period, prior to Check-in.&#xD;
&#xD;
          7. Has a body mass index greater than 40.0 kg/m2 or less than 18.0 kg/m2 at Screening.&#xD;
&#xD;
          8. Has a history of drug or alcohol abuse within 12 months of Screening.&#xD;
&#xD;
          9. Has a systolic BP &lt; 90 mmHg or &gt; 150 mmHg, diastolic BP &lt; 40 mmHg or &gt; 95 mmHg, or HR&#xD;
             &lt; 40 bpm or &gt; 99 bpm at Screening.&#xD;
&#xD;
         10. Is allergic to or intolerant of components of the product e-liquid, including but not&#xD;
             limited to, menthol, propylene glycol or glycerin.&#xD;
&#xD;
         11. Is unable to use the CReSS topography device with the vaping device during the&#xD;
             training session on Day -1.&#xD;
&#xD;
         12. Has an estimated creatinine clearance &lt; 70 mL/minute (using the Cockcroft Gault&#xD;
             equation) at Screening.&#xD;
&#xD;
         13. Has a positive urine drug or alcohol test at Screening or Check-in. A positive test&#xD;
             result for cannabinoids may be permitted if the result to the cannabis intoxication&#xD;
             evaluation is negative at Check-in.&#xD;
&#xD;
         14. If female, has a positive pregnancy test, is breastfeeding or lactating, or intends to&#xD;
             become pregnant from Screening through Day 5.&#xD;
&#xD;
         15. Has been treated for depression, diabetes, asthma, emphysema, or chronic obstructive&#xD;
             pulmonary disease within 12 months of Check-in.&#xD;
&#xD;
         16. Has previously been diagnosed with any form of cancer, except for basal cell or&#xD;
             squamous epithelial carcinomas of the skin that have been resected.&#xD;
&#xD;
         17. Has used medications known to interact with cytochrome P450 2A6 (including, but not&#xD;
             limited to, amiodarone, desipramine, isoniazid, ketoconazole, miconazole,&#xD;
             phenobarbital, rifampin, tranylcypromine, methoxsalen) within 6 weeks prior to&#xD;
             Check-in.&#xD;
&#xD;
         18. Has used a product containing pseudoephedrine within 48 hours prior to Check-in.&#xD;
&#xD;
         19. Has used any other tobacco- or nicotine-containing products other than closed-system&#xD;
             ENDS products (e.g., open-system ENDS, cigarettes, cigars, pipes, snuff, pouches,&#xD;
             chewing tobacco, nicotine inhalers, nicotine patches, nicotine sprays, nicotine&#xD;
             lozenges, or nicotine gum) within 7 days of Check-in.&#xD;
&#xD;
         20. Has used any products for the purpose of smoking/vaping cessation, including, but not&#xD;
             limited to, nicotine replacement therapies, varenicline (Chantix), or bupropion&#xD;
             (Zyban) from 30 days prior to Screening through Check-in.&#xD;
&#xD;
         21. Is a self-reported puffer (i.e., draws aerosol from the ENDS into the mouth and throat&#xD;
             but does not inhale).&#xD;
&#xD;
         22. Is postponing a planned vaping quit attempt in order to participate in the study.&#xD;
&#xD;
         23. Has donated plasma within 7 days prior to Check-in.&#xD;
&#xD;
         24. Has provided a whole blood donation, had significant blood loss, or received whole&#xD;
             blood or a blood product transfusion within 56 days prior to Check-in.&#xD;
&#xD;
         25. Has participated in a previous clinical study for a tobacco product or an&#xD;
             investigational drug, device, or biologic, within 30 days or 5 times the half-life of&#xD;
             the product (whichever is longer) prior to Check-in.&#xD;
&#xD;
         26. Is or has a first-degree relative (e.g., spouse, parent, sibling, child) who is a&#xD;
             current or former employee of a tobacco or ENDS manufacturer or is a named party or&#xD;
             class representative in litigation with the tobacco or ENDS industry.&#xD;
&#xD;
         27. Is or has a first-degree relative (e.g., spouse, parent, sibling, child) who is a&#xD;
             current employee of the clinic site(s).&#xD;
&#xD;
         28. Is or has a first-degree relative (e.g., spouse, parent, sibling, child) who is a&#xD;
             current employee of the Sponsor.&#xD;
&#xD;
         29. Has previously been withdrawn from or has completed this study.&#xD;
&#xD;
         30. In the opinion of an Investigator, the subject should not participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Graff, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor Representative</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global, Inc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas, Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electronic Nicotine Delivery System</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Abuse Liability</keyword>
  <keyword>Topography</keyword>
  <keyword>E-cigarette</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

